SAN FRANCISCO and BOSTON — September 3, 2025 — Leads & Copy — Apogee Therapeutics, Inc., (Nasdaq: APGE), will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m. E.T. A live and archived webcast will be available on the company’s website.
Apogee Therapeutics is a clinical-stage biotechnology company focused on optimized, novel biologics for Immune and Inflammatory (I&I) markets, including Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD). The company’s antibody programs target established mechanisms of action and incorporate advanced antibody engineering. APG777, Apogee’s lead program, is being developed for AD. Apogee has four validated targets and aims to achieve best-in-class profiles through monotherapies and combinations.
Investor Contact: Noel Kurdi, VP, Investor Relations, Apogee Therapeutics, Inc., noel.kurdi@apogeetherapeutics.com
Media Contact: Dan Budwick, 1AB, dan@1abmedia.com
Source: Apogee Therapeutics, Inc.
